Premium
Readthrough of stop codons by use of aminoglycosides in cells from xeroderma pigmentosum group C patients
Author(s) -
Kuschal Christiane,
Khan Sikandar G.,
Enk Benedikt,
DiGiovanna John J.,
Kraemer Kenneth H.
Publication year - 2015
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12655
Subject(s) - xeroderma pigmentosum , neomycin , aminoglycoside , ototoxicity , vinblastine , gentamicin , stop codon , medicine , gene , cancer research , biology , pharmacology , genetics , chemotherapy , antibiotics , cisplatin , dna repair
Readthrough of premature termination (stop) codons ( PTC ) is a new approach to treatment of genetic diseases. We recently reported that readthrough of PTC in cells from some xeroderma pigmentosum complementation group C ( XP ‐C) patients could be achieved with the aminoglycosides geneticin or gentamicin. We found that the response depended on several factors including the PTC sequence, its location within the gene and the aminoglycoside used. Here, we extended these studies to investigate the effects of other aminoglycosides that are already on the market. We reasoned that topical treatment could deliver much higher concentrations of drug to the skin, the therapeutic target, and thus increase the therapeutic effect while reducing renal or ototoxicity in comparison with systemic treatment. Our prior clinical studies indicated that only a few percent of normal XPC expression was associated with mild clinical disease. We found minimal cell toxicity in the XP ‐C cells with several aminoglycosides. We found increased XPC mRNA expression in PTC ‐containing XP ‐C cells with G418, paromomycin, neomycin and kanamycin and increased XPC protein expression with G418. We conclude that in selected patients with XP , topical PTC therapy can be investigated as a method of personalized medicine to alleviate their cutaneous symptoms.